CDC Details Protocol for Influenza Candidate Vaccine Virus Production

The U.S. Centers for Disease Control and Prevention (CDC) has recently published its methodology for developing influenza candidate vaccine viruses (CVVs). This protocol is designed to facilitate the smooth transition from CVV development to vaccine manufacturing, ensuring the timely production of pandemic influenza vaccines by adhering to strict Quality System Requirements (QSR) and World Health Organization (WHO) guidelines.

This protocol aims to support the efficient transition from CVV development to vaccine manufacturing, ensuring pandemic influenza vaccines can be produced when required.

Background on Pandemic Vaccine Efforts

Influenza is a significant global health threat, contributing to an estimated 650,000 deaths annually. The emergence of a new pandemic strain could have even more severe consequences. Vaccination remains a critical strategy for protection against infectious outbreaks.

The CDC, in collaboration with entities such as the U.S. National Institutes of Health and the WHO, plays a crucial role in developing and maintaining CVVs. Furthermore, U.S. government programs, including the Biomedical Advanced Research and Development Authority (BARDA), support extensive vaccine stockpiling efforts specifically targeting influenza A lineages identified with high pandemic potential. These CVVs developed at the CDC are specifically optimized for growth in chicken eggs, which serve as the primary vaccine seeds for mass production.

The CVV Production Process

The CDC produces its CVVs by following WHO guidelines and leveraging its robust Quality Management Systems (QMS) and dedicated Quality Assurance Unit (QAU) to ensure full regulatory compliance throughout the process.

The intricate process involves several key steps:

1. Workspace Decontamination: The initial step ensures that the production environment is completely free of contaminants.
2. Material Inspection: The QAU meticulously inspects all raw materials and reagents. Comprehensive documentation is maintained for thorough review.
3. Virus Identification: Through global surveillance conducted by the WHO Global Influenza Surveillance and Response System (GISRS), scientists identify influenza viruses exhibiting pandemic potential. This includes characterizing novel hemagglutinin (HA) and neuraminidase (NA) gene sequences.
4. Gene Cloning: The identified HA and NA sequences are cloned into influenza reverse-genetics plasmids. These plasmids are then purified and sequenced to confirm their genetic integrity.
5. Virus Production Initiation: Vero cells are transfected with the confirmed plasmids to initiate the production of the virus.
6. Mass Production: Once isolated and validated, these viruses are introduced into embryonated chicken eggs for large-scale production.
7. Functional Confirmation: The HA assay is performed to measure viral content. Eggs containing the most diluted HA content are carefully selected to generate a working stock, a method designed to minimize the presence of mixed viral populations.

Quality Assurance Measures

Every CVV undergoes rigorous evaluation against a comprehensive set of quality criteria. These include assessments for identity, purity, titer, genetic stability, antigenicity, attenuation, and various biosafety characteristics.

Conclusion and Future Outlook

This detailed protocol serves as a crucial guide for the CDC's production of influenza CVVs, specifically for potential pandemic deployment. To date, over 100 CVVs have been produced, with 36 already distributed to manufacturers and researchers globally.

Over 100 CVVs have been produced, with 36 distributed to manufacturers and researchers.

Despite its effectiveness, this traditional method presents certain limitations, such as the potential for egg-adaptive mutations, vulnerabilities in the supply chain, and variations in production quantities. To address these challenges and enhance pandemic responsiveness, ongoing advancements in recombinant protein- and nucleic acid-based vaccine platforms are offering promising alternative strategies for rapid antigen redesign and production.